A pharmacist who dispenses through an unresolved red flag and a pharmacist who reflexively refuses every unusual prescription can end up in the same DEA file. Federal law places an independent corresponding responsibility on the pharmacist who fills a controlled substance prescription, not just the prescriber who writes it, and DEA increasingly measures that responsibility by what the pharmacy documented at the counter. A pharmacist-in-charge who cannot produce a contemporaneous record of how a red flag was investigated and resolved is exposed even when the underlying fill was legitimate.
The Corresponding Responsibility Standard
Under 21 CFR 1306.04(a), the responsibility for the proper prescribing and dispensing of controlled substances is upon the prescribing practitioner, but a corresponding responsibility rests with the pharmacist who fills the prescription. DEA and the courts read that sentence as an independent, non-delegable duty: a facially valid signature and a valid DEA registration number on the prescription do not end the pharmacist's inquiry. If a red flag exists, the pharmacist has to investigate it and resolve the concern before dispensing, and reliance on the prescriber alone does not satisfy the standard.
What Counts as a Red Flag
DEA has not published a fixed checklist of red flags. The categories pharmacists are expected to recognize come from DEA Final Orders and case law, and they cluster around a handful of patterns: cash payment for high-dose opioids the patient's insurance would otherwise cover, an opioid prescribed together with a benzodiazepine and carisoprodol, multiple prescribers or multiple pharmacies showing up in the same patient's PDMP history, out-of-state prescribers writing identical quantities for patients who traveled a long distance to the pharmacy, and early refills paired with dose escalation. None of these facts alone forces a refusal. Each one triggers an obligation to look further before the prescription is filled.
Documenting Resolution, Not Reflexive Refusal
DEA credits investigation, not an automatic decline or a fill with no questions asked: a call to the prescriber's office confirming the diagnosis and intended treatment, a PDMP query pulled and reviewed at the time of the fill, and a conversation with the patient about therapy history and prior fills. What protects the pharmacy afterward is the documentation of that process, not the pharmacist's recollection of it. Contemporaneous notes should record which red flag was identified, the specific steps taken to resolve it, and the clinical basis for the decision to dispense or decline. Notes written after DEA opens an inquiry carry far less weight than notes entered in the dispensing system at the time of the fill.
The documentation of how a red flag was resolved is often the only evidence that separates a defensible fill from a DEA registration action.
The enforcement backdrop is not abstract. In April 2025, Walgreens agreed to pay up to $350 million to resolve Department of Justice allegations that it filled unlawful opioid prescriptions and billed federal healthcare programs for them, a settlement that came with a seven-year DEA compliance agreement built around prescription validation. Individual pharmacies face a steeper cliff: a documented pattern of unresolved red flags can support a DEA order to show cause questioning the registration itself, and where DEA treats the deficiency as an imminent danger to public health, an immediate suspension order before any hearing.
That evidentiary value survives even as the legal standard narrows. In February 2026, the Fifth Circuit held in Neumann's Pharm., L.L.C. v. DEA that federal criminal liability under the Controlled Substances Act requires proof a pharmacist actually knew a prescription was invalid, rejecting DEA's longstanding "knows or has reason to know" theory. The holding is limited to criminal liability inside the Fifth Circuit and leaves DEA's registration and administrative enforcement authority untouched. A documented PDMP check and prescriber call remain the clearest evidence of what the pharmacist actually knew at the time of the fill.
Why Early Legal Counsel Is Critical
It is critical that pharmacies promptly retain experienced healthcare defense counsel once a DEA inquiry into red flag resolution begins, not after a show cause order arrives. Early legal intervention shapes how the dispensing and documentation record gets presented to DEA, which staff get interviewed and how, and it lets counsel communicate with the Diversion Field Office on the pharmacy's behalf during a DEA inspection. Delaying representation until DEA has already drawn its own conclusions from an incomplete record can mean defending decisions the pharmacy never had the chance to explain.
How Health Law Alliance Can Help
Health Law Alliance represents pharmacies and pharmacists-in-charge through DEA red flag inquiries, corresponding responsibility investigations, and the order to show cause and immediate suspension order proceedings that can follow, as part of the firm's DEA defense practice. If your pharmacy is building or defending its red flag documentation practices, contact us for a free, confidential consultation.
